Alexion Pharmaceuticals, Inc. (ALXN)
ALXN Price and Sentiment
ALXN Latest news
AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to lack of efficacy in a late-stage trial. Following an interim analysis, Alexion says it will scrap a Phase 3 study testing the long-acting C5 inhibitor Ultomiris as a treatment for amyotrophic lateral sclerosis.
AstraZeneca PLC has announced higher full-year guidance to include the newly acquired Alexion, after the transaction was completed last week. The pharma giant expects total revenue to jump 21-22%, with core earnings per share (EPS) from US$5.05 to US$5.40.
AstraZeneca PLC (LON:AZN) announced that Alexion's Ultomiris has been recommended for marketing authorisation in the EU for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on interim results from the Phase III clinical trial in children and teens with PNH.
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. TECH: Which Stock Is the Better Value Option?
Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48% increase over the same period in 2020.
With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.
What did the stock market do today? It saw Moderna reach a major index, it saw Americans spending big, and it saw Biden targeting China.
Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.